Literature DB >> 23555182

ERK2-regulated TIMP1 induces hyperproliferation of K-Ras(G12D)-transformed pancreatic ductal cells.

Gregory P Botta1, Maximilian Reichert, Mauricio J Reginato, Steffen Heeg, Anil K Rustgi, Peter I Lelkes.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) commonly contains a mutation in K-Ras(G12D) and is characterized by a desmoplastic reaction composed of deregulated, proliferating cells embedded in an abnormal extracellular matrix (ECM). Our previous observations imply that inhibiting the mitogen-activated protein kinase (MAPK)-extracellular signal-regulated kinase (ERK2) kinase signal pathway reverses a matrix metalloproteinase 1-specific invasive phenotype. Here, we investigated the specific genes downstream of MAPK-ERK2 responsible for the hyperproliferative abilities of human and murine primary ductal epithelial cells (PDCs) within an ECM. Compared with control, DNA synthesis and total cell proliferation was significantly increased in human PDCs harboring the PDAC common p53, Rb/p16(INK4a), and K-Ras (G12D) mutations. Both of these effects were readily reversed following small-molecule inhibition or lentiviral silencing of ERK2. Microarray analysis of PDCs in three-dimensional (3D) culture revealed a unique, MAPK-influenced gene signature downstream of K-Ras (G12D). Unbiased hierarchical analysis permitted filtration of tissue inhibitor of matrix metalloproteinase 1 (TIMP1). Pancreatic cells isolated from Pdx1-Cre; LSL-K-ras(G12D/+)-mutated mice exhibit increased TIMP1 RNA transcription compared to wild-type littermate controls. Analyses of both 3D, in vitro human K-Ras (G12D) PDCs and data mining of publicly annotated human pancreatic data sets correlatively indicate increased levels of TIMP1 RNA. While silencing TIMP1 did not significantly effect PDC proliferation, exogenous addition of human recombinant TIMP1 significantly increased proliferation but only in transformed K-Ras (G12D) PDCs in 3D. Overall, TIMP1 is an upregulated gene product and a proliferative inducer of K-Ras(G12D)-mutated PDCs through the ERK2 signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23555182      PMCID: PMC3612909          DOI: 10.1593/neo.121708

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  58 in total

1.  Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma.

Authors:  S R Bramhall; J P Neoptolemos; G W Stamp; N R Lemoine
Journal:  J Pathol       Date:  1997-07       Impact factor: 7.996

2.  Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein.

Authors:  Ki-Kyung Jung; Xu-Wen Liu; Rosemarie Chirco; Rafael Fridman; Hyeong-Reh Choi Kim
Journal:  EMBO J       Date:  2006-08-17       Impact factor: 11.598

Review 3.  Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion.

Authors:  Dimitra Bourboulia; William G Stetler-Stevenson
Journal:  Semin Cancer Biol       Date:  2010-05-12       Impact factor: 15.707

4.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Authors:  E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

5.  Growth factor-dependent activation of the Ras-Raf-MEK-MAPK pathway in the human pancreatic carcinoma cell line PANC-1 carrying activated K-ras: implications for cell proliferation and cell migration.

Authors:  K Giehl; B Skripczynski; A Mansard; A Menke; P Gierschik
Journal:  Oncogene       Date:  2000-06-08       Impact factor: 9.867

6.  Adenoviral delivery of TIMP1 or TIMP2 can modify the invasive behavior of pancreatic cancer and can have a significant antitumor effect in vivo.

Authors:  A S Rigg; N R Lemoine
Journal:  Cancer Gene Ther       Date:  2001-11       Impact factor: 5.987

7.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

8.  Successful growth and characterization of mouse pancreatic ductal cells: functional properties of the Ki-RAS(G12V) oncogene.

Authors:  Franz S Schreiber; Therese B Deramaudt; Thomas B Brunner; Michael I Boretti; Keith J Gooch; Doris A Stoffers; Eric J Bernhard; Anil K Rustgi
Journal:  Gastroenterology       Date:  2004-07       Impact factor: 22.682

9.  Single and combined silencing of ERK1 and ERK2 reveals their positive contribution to growth signaling depending on their expression levels.

Authors:  Renaud Lefloch; Jacques Pouysségur; Philippe Lenormand
Journal:  Mol Cell Biol       Date:  2007-10-29       Impact factor: 4.272

10.  Stabilization of beta-catenin induces pancreas tumor formation.

Authors:  Patrick W Heiser; David A Cano; Limor Landsman; Grace E Kim; James G Kench; David S Klimstra; Maketo M Taketo; Andrew V Biankin; Matthias Hebrok
Journal:  Gastroenterology       Date:  2008-07-09       Impact factor: 22.682

View more
  11 in total

1.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

2.  Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.

Authors:  Michela Capello; Leonidas E Bantis; Ghislaine Scelo; Yang Zhao; Peng Li; Dilsher S Dhillon; Nikul J Patel; Deepali L Kundnani; Hong Wang; James L Abbruzzese; Anirban Maitra; Margaret A Tempero; Randall Brand; Matthew A Firpo; Sean J Mulvihill; Matthew H Katz; Paul Brennan; Ziding Feng; Ayumu Taguchi; Samir M Hanash
Journal:  J Natl Cancer Inst       Date:  2017-04-01       Impact factor: 13.506

3.  Rigidity controls human desmoplastic matrix anisotropy to enable pancreatic cancer cell spread via extracellular signal-regulated kinase 2.

Authors:  R Malik; T Luong; X Cao; B Han; N Shah; J Franco-Barraza; L Han; V B Shenoy; P I Lelkes; E Cukierman
Journal:  Matrix Biol       Date:  2018-11-07       Impact factor: 11.583

Review 4.  Molecular aspects of prostate cancer with neuroendocrine differentiation.

Authors:  Qi Li; Connie S Zhang; Yifen Zhang
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

5.  HuoXueJieDu Formula Alleviates Diabetic Retinopathy in Rats by Inhibiting SOCS3-STAT3 and TIMP1-A2M Pathways.

Authors:  Hongliang Wang; Wei Xing; Shijie Tang; Zhenglin Wang; Tiantian Lv; Yan Wu; Shuzhen Guo; Chun Li; Jing Han; Ruixin Zhu; Wei Wang
Journal:  Int J Genomics       Date:  2017-11-29       Impact factor: 2.326

6.  Comparative proteomics of a model MCF10A-KRasG12V cell line reveals a distinct molecular signature of the KRasG12V cell surface.

Authors:  Xiaoying Ye; King C Chan; Andrew M Waters; Matthew Bess; Adam Harned; Bih-Rong Wei; Jadranka Loncarek; Brian T Luke; Benjamin C Orsburn; Bradley D Hollinger; Robert M Stephens; Rachel Bagni; Alex Martinko; James A Wells; Dwight V Nissley; Frank McCormick; Gordon Whiteley; Josip Blonder
Journal:  Oncotarget       Date:  2016-12-27

7.  The Mutant p53-Driven Secretome Has Oncogenic Functions in Pancreatic Ductal Adenocarcinoma Cells.

Authors:  Giovanna Butera; Jessica Brandi; Chiara Cavallini; Aldo Scarpa; Rita T Lawlor; Maria Teresa Scupoli; Emílio Marengo; Daniela Cecconi; Marcello Manfredi; Massimo Donadelli
Journal:  Biomolecules       Date:  2020-06-09

8.  Prox1-Heterozygosis Sensitizes the Pancreas to Oncogenic Kras-Induced Neoplastic Transformation.

Authors:  Yiannis Drosos; Geoffrey Neale; Jianming Ye; Leena Paul; Emin Kuliyev; Anirban Maitra; Anna L Means; M Kay Washington; Jerold Rehg; David B Finkelstein; Beatriz Sosa-Pineda
Journal:  Neoplasia       Date:  2016-03       Impact factor: 5.715

9.  TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer.

Authors:  Line S Tarpgaard; Maj Sofie Ørum-Madsen; Ib J Christensen; Cathrine Nordgaard; Julie Noer; Tormod K Guren; Bengt Glimelius; Halfdan Sorbye; Tone Ikdahl; Elin H Kure; Kjell M Tveit; Hans J Nielsen; Per Pfeiffer; Nils Brünner; José M A Moreira
Journal:  Oncotarget       Date:  2016-09-13

10.  Metallopeptidase inhibitor 1 (TIMP-1) promotes receptor tyrosine kinase c-Kit signaling in colorectal cancer.

Authors:  Cathrine Nordgaard; Sophia Doll; Ana Laura de Souza Almeida Matos; Mikkel Høeberg; Julhash Uddin Kazi; Stine Friis; Jan Stenvang; Lars Rönnstrand; Matthias Mann; José Manuel Afonso Moreira
Journal:  Mol Oncol       Date:  2019-10-24       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.